189 related articles for article (PubMed ID: 33288675)
1. Direct evidence that the GPCR CysLTR2 mutant causative of uveal melanoma is constitutively active with highly biased signaling.
Ceraudo E; Horioka M; Mattheisen JM; Hitchman TD; Moore AR; Kazmi MA; Chi P; Chen Y; Sakmar TP; Huber T
J Biol Chem; 2021; 296():100163. PubMed ID: 33288675
[TBL] [Abstract][Full Text] [Related]
2. Involvement of mutant and wild-type CYSLTR2 in the development and progression of uveal nevi and melanoma.
Nell RJ; Menger NV; Versluis M; Luyten GPM; Verdijk RM; Madigan MC; Jager MJ; van der Velden PA
BMC Cancer; 2021 Feb; 21(1):164. PubMed ID: 33588787
[TBL] [Abstract][Full Text] [Related]
3. Activating cysteinyl leukotriene receptor 2 (CYSLTR2) mutations in blue nevi.
Möller I; Murali R; Müller H; Wiesner T; Jackett LA; Scholz SL; Cosgarea I; van de Nes JA; Sucker A; Hillen U; Schilling B; Paschen A; Kutzner H; Rütten A; Böckers M; Scolyer RA; Schadendorf D; Griewank KG
Mod Pathol; 2017 Mar; 30(3):350-356. PubMed ID: 27934878
[TBL] [Abstract][Full Text] [Related]
4. Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma.
Moore AR; Ceraudo E; Sher JJ; Guan Y; Shoushtari AN; Chang MT; Zhang JQ; Walczak EG; Kazmi MA; Taylor BS; Huber T; Chi P; Sakmar TP; Chen Y
Nat Genet; 2016 Jun; 48(6):675-80. PubMed ID: 27089179
[TBL] [Abstract][Full Text] [Related]
5. Bioinformatics analysis of GNAQ, GNA11, BAP1, SF3B1,SRSF2, EIF1AX, PLCB4, and CYSLTR2 genes and their role in the pathogenesis of Uveal Melanoma.
Akin-Bali DF
Ophthalmic Genet; 2021 Dec; 42(6):732-743. PubMed ID: 34353217
[TBL] [Abstract][Full Text] [Related]
6. Mutations of GNAQ, GNA11, SF3B1, EIF1AX, PLCB4 and CYSLTR in Uveal Melanoma in Chinese Patients.
Hou C; Xiao L; Ren X; Tang F; Guo B; Zeng W; Liang C; Yan N
Ophthalmic Res; 2020; 63(3):358-368. PubMed ID: 31614358
[TBL] [Abstract][Full Text] [Related]
7. Uveal Melanomas Harbor Recurrent Activating Mutations in CYSLTR2.
Cancer Discov; 2016 Jun; 6(6):573. PubMed ID: 27150534
[TBL] [Abstract][Full Text] [Related]
8. Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP.
Yu FX; Luo J; Mo JS; Liu G; Kim YC; Meng Z; Zhao L; Peyman G; Ouyang H; Jiang W; Zhao J; Chen X; Zhang L; Wang CY; Bastian BC; Zhang K; Guan KL
Cancer Cell; 2014 Jun; 25(6):822-30. PubMed ID: 24882516
[TBL] [Abstract][Full Text] [Related]
9. Functional characterization of uveal melanoma oncogenes.
Ma J; Weng L; Bastian BC; Chen X
Oncogene; 2021 Jan; 40(4):806-820. PubMed ID: 33262460
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of oncogenic cysteinyl leukotriene receptor 2 as a therapeutic target for uveal melanoma.
Slater K; Hoo PS; Buckley AM; Piulats JM; Villanueva A; Portela A; Kennedy BN
Cancer Metastasis Rev; 2018 Sep; 37(2-3):335-345. PubMed ID: 30094568
[TBL] [Abstract][Full Text] [Related]
11. Combined Inhibition of Gα
Hitchman TD; Bayshtok G; Ceraudo E; Moore AR; Lee C; Jia R; Wang N; Pachai MR; Shoushtari AN; Francis JH; Guan Y; Chen J; Chang MT; Taylor BS; Sakmar TP; Huber T; Chi P; Chen Y
Clin Cancer Res; 2021 Mar; 27(5):1476-1490. PubMed ID: 33229459
[TBL] [Abstract][Full Text] [Related]
12. Biased signaling of the angiotensin II type 1 receptor can be mediated through distinct mechanisms.
Bonde MM; Hansen JT; Sanni SJ; Haunsø S; Gammeltoft S; Lyngsø C; Hansen JL
PLoS One; 2010 Nov; 5(11):e14135. PubMed ID: 21152433
[TBL] [Abstract][Full Text] [Related]
13. Targeting primary and metastatic uveal melanoma with a G protein inhibitor.
Onken MD; Makepeace CM; Kaltenbronn KM; Choi J; Hernandez-Aya L; Weilbaecher KN; Piggott KD; Rao PK; Yuede CM; Dixon AJ; Osei-Owusu P; Cooper JA; Blumer KJ
J Biol Chem; 2021; 296():100403. PubMed ID: 33577798
[TBL] [Abstract][Full Text] [Related]
14. β-Arrestin Recruitment and Biased Agonism at Free Fatty Acid Receptor 1.
Mancini AD; Bertrand G; Vivot K; Carpentier É; Tremblay C; Ghislain J; Bouvier M; Poitout V
J Biol Chem; 2015 Aug; 290(34):21131-21140. PubMed ID: 26157145
[TBL] [Abstract][Full Text] [Related]
15. A G Protein-biased Designer G Protein-coupled Receptor Useful for Studying the Physiological Relevance of Gq/11-dependent Signaling Pathways.
Hu J; Stern M; Gimenez LE; Wanka L; Zhu L; Rossi M; Meister J; Inoue A; Beck-Sickinger AG; Gurevich VV; Wess J
J Biol Chem; 2016 Apr; 291(15):7809-20. PubMed ID: 26851281
[TBL] [Abstract][Full Text] [Related]
16. Research in practice: Therapeutic targeting of oncogenic GNAQ mutations in uveal melanoma.
Gaffal E
J Dtsch Dermatol Ges; 2020 Nov; 18(11):1245-1248. PubMed ID: 32954611
[TBL] [Abstract][Full Text] [Related]
17. Oncogenic signaling in uveal melanoma.
Park JJ; Diefenbach RJ; Joshua AM; Kefford RF; Carlino MS; Rizos H
Pigment Cell Melanoma Res; 2018 Nov; 31(6):661-672. PubMed ID: 29738114
[TBL] [Abstract][Full Text] [Related]
18. Biased signaling through G-protein-coupled PROKR2 receptors harboring missense mutations.
Sbai O; Monnier C; Dodé C; Pin JP; Hardelin JP; Rondard P
FASEB J; 2014 Aug; 28(8):3734-44. PubMed ID: 24830383
[TBL] [Abstract][Full Text] [Related]
19. Dysregulated GPCR Signaling and Therapeutic Options in Uveal Melanoma.
Chua V; Lapadula D; Randolph C; Benovic JL; Wedegaertner PB; Aplin AE
Mol Cancer Res; 2017 May; 15(5):501-506. PubMed ID: 28223438
[TBL] [Abstract][Full Text] [Related]
20. Mutant GNAQ promotes cell viability and migration of uveal melanoma cells through the activation of Notch signaling.
Liu H; Lei C; Long K; Yang X; Zhu Z; Zhang L; Liu J
Oncol Rep; 2015 Jul; 34(1):295-301. PubMed ID: 25955651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
